Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8591408 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL5610713 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL30335844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL28520844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL6657589 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| Hydrochloric Acid SCHEMBL30833067 | 0.98 | PYGB (0.42) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520861 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520885 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL7134097 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL27920926 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | claimed |
| EP-4748382-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748381-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-04-30 | — | — | US | disclosed |
| EP-3826720-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | SILENCE THERAPEUTICS GMBH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658263-A2 | COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS | Yale University (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20220340634-A1 | PHARMACEUTICAL PREPARATION COMPRISING RECOMBINANT HCG | Frering B.V. (NL) | 2022-10-27 | — | — | US | disclosed |
| US-20220331351-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | SILENCE THERAPEUTICS GMBH (DE) | 2022-10-20 | — | — | US | disclosed |
| US-20220290143-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2022-09-15 | — | — | US | disclosed |
| US-11414660-B2 | Products and compositions | SILENCE THERAPEUTICS GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| EP-4029942-A1 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| US-20220184148-A1 | MICROBIOME RESPONSE TO AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-06-16 | — | — | US | disclosed |
| US-20220089579-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220090067-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| CN-112334582-A | Method for producing protein | 花王株式会社 | 2021-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | PYGB 1006/4885PYGL 510/4885PYGM 1446/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | PYGB 682/4885PYGL 179/4885PYGM 300/4885 |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | PYGB 1744/4885PYGL 3204/4885PYGM 4216/4885 |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, FCGR2A | PYGB 1332/4885PYGL 1480/4885PYGM 721/4885 |
| US-20220089579-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | PYGB 1398/4885PYGL 890/4885PYGM 1217/4885 |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | CD74, HLA-DRB1, CD69 | PYGB 3333/4885PYGL 206/4885PYGM 2220/4885 |
| US-20220331351-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | TMPRSS6, TMPRSS4, TFRC | PYGB 2659/4885PYGL 1078/4885PYGM 2109/4885 |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, LDLR | PYGB 1315/4885PYGL 1281/4885PYGM 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.